TTD | Drug: D0L0ZC

Drug General Information
Drug ID	D0L0ZC
Former ID	DCL001089
Drug Name	GSK1059615
Drug Type	Small molecular drug
Indication	Metastatic breast cancer; Endometrial cancer; Lymphoma [ICD9: 140-199, 140-229, 174, 175, 182.0, 202.8, 210-229; ICD10:C50, C81-C86]		Discontinued in Phase 1	[548760]
Company	GlaxoSmithKline
Formula	C18H11N3O2S
Canonical SMILES	C1=CC2=NC=CC(=C2C=C1C=C3C(=O)NC(=O)S3)C4=CC=NC=C4
InChI	1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)
InChIKey	QDITZBLZQQZVEE-UHFFFAOYSA-N
PubChem Compound ID	71317162
PubChem Substance ID	162263913, 163125258, 174006469, 246373910
Target and Pathway
Target(s)	Phosphoinositide 3 kinase	Target Info	Inhibitor	[537633]
KEGG Pathway	Inositol phosphate metabolism
	ErbB signaling pathway
	Ras signaling pathway
	Rap1 signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Chemokine signaling pathway
	HIF-1 signaling pathway
	FoxO signaling pathway
	Phosphatidylinositol signaling system
	Sphingolipid signaling pathway
	mTOR signaling pathway
	PI3K-Akt signaling pathway
	AMPK signaling pathway
	Apoptosis
	Adrenergic signaling in cardiomyocytes
	VEGF signaling pathway
	Osteoclast differentiation
	Focal adhesion
	Signaling pathways regulating pluripotency of stem cells
	Platelet activation
	Toll-like receptor signaling pathway
	Jak-STAT signaling pathway
	Natural killer cell mediated cytotoxicity
	T cell receptor signaling pathway
	B cell receptor signaling pathway
	Fc epsilon RI signaling pathway
	Fc gamma R-mediated phagocytosis
	TNF signaling pathway
	Leukocyte transendothelial migration
	Neurotrophin signaling pathway
	Cholinergic synapse
	Inflammatory mediator regulation of TRP channels
	Regulation of actin cytoskeleton
	Insulin signaling pathway
	Progesterone-mediated oocyte maturation
	Estrogen signaling pathway
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Oxytocin signaling pathway
	Regulation of lipolysis in adipocytes
	Type II diabetes mellitus
	Non-alcoholic fatty liver disease (NAFLD)
	Aldosterone-regulated sodium reabsorption
	Carbohydrate digestion and absorption
	Bacterial invasion of epithelial cells
	Chagas disease (American trypanosomiasis)
	Toxoplasmosis
	Amoebiasis
	Hepatitis C
	Hepatitis B
	Measles
	Influenza A
	HTLV-I infection
	Epstein-Barr virus infection
	Pathways in cancer
	Viral carcinogenesis
	Proteoglycans in cancer
	MicroRNAs in cancer
	Colorectal cancer
	Renal cell carcinoma
	Pancreatic cancer
	Endometrial cancer
	Glioma
Prostate cancer
Melanoma
Chronic myeloid leukemia
Acute myeloid leukemia
Small cell lung cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
Choline metabolism in cancer
PathWhiz Pathway	Inositol Metabolism
	Phosphatidylinositol Phosphate Metabolism
	Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
	Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
	Fc Epsilon Receptor I Signaling in Mast Cells
Reactome	PI3K Cascade
	GPVI-mediated activation cascade
	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
	PI3K events in ERBB4 signaling
	PIP3 activates AKT signaling
	GAB1 signalosome
	PI3K events in ERBB2 signaling
	PI3K/AKT activation
	Role of phospholipids in phagocytosis
	Tie2 Signaling
	Constitutive Signaling by Aberrant PI3K in Cancer
	DAP12 signaling
	Role of LAT2/NTAL/LAB on calcium mobilization
	Nephrin interactions
	Costimulation by the CD28 family
	CD28 dependent PI3K/Akt signaling
	G beta:gamma signalling through PI3Kgamma
	G alpha (q) signalling events
	G alpha (12/13) signalling events
	VEGFA-VEGFR2 Pathway
	Interleukin-3, 5 and GM-CSF signaling
	Constitutive Signaling by EGFRvIII
	PI-3K cascade:FGFR1
	PI-3K cascade:FGFR2
	PI-3K cascade:FGFR3
	PI-3K cascade:FGFR4
	Interleukin receptor SHC signaling
	Regulation of signaling by CBL
WikiPathways	Toll-like receptor signaling pathway
	Serotonin HTR1 Group and FOS Pathway
	DNA Damage Response (only ATM dependent)
	G13 Signaling Pathway
	Regulation of Actin Cytoskeleton
	Insulin Signaling
	IL-4 Signaling Pathway
	Copper homeostasis
	Signaling of Hepatocyte Growth Factor Receptor
	Transcriptional activation by NRF2
	IL1 and megakaryotyces in obesity
	Signaling by ERBB4
	Signaling by ERBB2
	Fc epsilon receptor (FCERI) signaling
	PI Metabolism
	Interleukin-2 signaling
	Fcgamma receptor (FCGR) dependent phagocytosis
	Signaling by SCF-KIT
	DAP12 interactions
	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
	Gastrin-CREB signalling pathway via PKC and MAPK
	PIP3 activates AKT signaling
	Integrated Pancreatic Cancer Pathway
	Prostate Cancer
	Signaling Pathways in Glioblastoma
	TSLP Signaling Pathway
	Regulation of Microtubule Cytoskeleton
	TSH signaling pathway
	SREBP signalling
	TCR signaling
	Signaling by PDGF
	Signaling by Insulin receptor
	Signaling by FGFR
	Signaling by EGFR
	NGF signalling via TRKA from the plasma membrane
	Nephrin interactions
	Interleukin-3, 5 and GM-CSF signaling
	GPVI-mediated activation cascade
	GPCR downstream signaling
	Costimulation by the CD28 family
	Cell surface interactions at the vascular wall
	MicroRNAs in cardiomyocyte hypertrophy
	Angiogenesis
	Regulation of toll-like receptor signaling pathway
	AMPK Signaling
References
Ref 548760	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028447)
Ref 537633	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information